This trial is evaluating whether Semaglutide Injectable Product will improve 4 primary outcomes, 9 secondary outcomes, and 2 other outcomes in patients with Obesity. Measurement will happen over the course of 56 weeks.
This trial requires 104 total participants across 2 different treatment groups
This trial involves 2 different treatments. Semaglutide Injectable Product is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Overweight individuals generally have a higher risk of developing non-communicable diseases such as diabetes, heart disease and osteoarthritis. Obesity increases the risk of developing diabetes, and it causes high blood pressure and increases the risk of developing cardiovascular diseases such as ischemic heart disease." - Anonymous Online Contributor
"Obesity is defined by a BMI at or above > or=30 kg/m(2) in men or > or =27 kg/m(2) or > or =26 kg/m(2) in women. The signs of obesity are swelling of the face and neck (a adipose facies), high blood pressure, high cholesterol, and high blood sugar levels. People with signs of obesity should be evaluated with a cardiologist for liposuction and diet counselling." - Anonymous Online Contributor
"Obesity (defined as a BMI ≥30 kg/m) is a common condition that influences both short-term and long-term health. There is no single disease entity associated with obesity." - Anonymous Online Contributor
"The mainstay of obesity treatment seems to be behavioral modification and exercise. There are no prescription drugs approved for the treatment of obesity. There is limited research on the effectiveness of cognitive behavioral therapy for obesity. It is a plausible treatment option because it is safe and effective. At least one prescription drug, sibutramine, approved by the United States Food and Drug Administration is available. Because of concerns of cardiovascular side-effect, this drug is not ideal for everyone. In general, behavioral weight loss and exercise treatment are effective methods that will not only make the patients feel better, but will also help them maintain overall health." - Anonymous Online Contributor
"Approximately 35.0%, or approximately 74.4 million adults, will be overweight by 2022. More than 9.4%, or approximately 22.4% of adults, will be obese by 2022." - Anonymous Online Contributor
"Obesity should be managed as early as possible, with weight loss being the best method to prevent or reduce the incidence of future cancer. Obesity and cancer are more common when the body mass increases as the result of a low body mass or cachexia." - Anonymous Online Contributor
"There have been new discoveries for treating obesity. There has been research on finding chemicals in foods that may prevent the body from storing fats and getting rid of carbohydrates that build up. And there has been research on finding a certain bacterium that could digest and break down the body's own fat stores without being harmful. Research has found that many of these bacteria are found in small amounts in many common foods. Some of these bacteria are found in foods like beans, soy, tomatoes and other vegetables. And research showed that these bacteria may be beneficial to treat obesity because they break down body fats, but they could also cause diarrhea." - Anonymous Online Contributor
"The use of the semaglutide product was not associated with any additional or increased utilization for other indications. Although no statistically significant difference was presented for utilization of semaglutide and metformin, other medications could be significantly affected by semaglutide use. This is an observational study; as such, no causal conclusions can be drawn from this data." - Anonymous Online Contributor
"Obesity has a huge impact upon health worldwide especially for the developing countries. The prevalence has reached alarming proportions when compared to the previous years where the mean BMI has decreased significantly in the western countries. This rapid change was the cause of different researchers and scientists working in many parts of the world especially in the developing countries. Furthermore, the obese population represents a group of patients that have many unique challenges when managing their disease as well as the problems when living a healthy lifestyle. Obesity is an important issue that needs further investigation for understanding the underlying mechanisms linking obesity to different disease pathologies such as diabetes, ischaemic heart disease, cancer, inflammatory diseases and some neurological disorders." - Anonymous Online Contributor
"Results from a recent clinical trial contradict most of the existing studies about obesity being either a genetic or environmental disease. To our knowledge, this is the first time that the authors' data is used to study the impact of familial factors in an effort to determine the genetic component of obesity. Results from a recent clinical trial suggest that there are at least two possible scenarios: the genetic and the environmental factors could act on the same people at the same time. If our data is true, then obesity could be considered a multifactorial disease. If that is what we saw in our data, then we are back to a new view of the disease and the new possibility of treating it. We look forward to further studying this relationship using the same data in new studies." - Anonymous Online Contributor
"Obesity is a multifactorial condition with multiple causes, but it is primarily a function of a predisposition to increased adiposity and less physical activity, which may be the consequence of lifestyle factors including social inequality." - Anonymous Online Contributor
"Based on these data, semaglutide showed potential to improve cardiovascular risk factors and a reduction in the progression of atherosclerosis in patients with type 2 diabetes." - Anonymous Online Contributor